MedTrace Logo

Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism.

NCT03199430 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-06-27

No results posted yet for this study

Summary

The aim of this study was to explore the impact of acute ingestion of the polyphenol epigallocatechin galate (EGCG) on catecholamine, catecholamine metabolite, systemic metabolic and cardio-vascular variables across a range of exercise intensities during graded cycle exercise in man.

Conditions

  • EGCG Influence on Catecholamine Metabolism

Interventions

DIETARY_SUPPLEMENT

Epigallocatechin gallate

DIETARY_SUPPLEMENT

Placebo

1450mg Corn Flour

Sponsors & Collaborators

  • Swansea University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-01-31
Completion
2016-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199430 on ClinicalTrials.gov